Clinical Trials

Clinical Trials

Phase II Clinical Trial currently open for participation:

-------------------------------------------------------------------------------------------------------------------------------------

Study: NCT04486781

Description: A Phase II trial of pembrolizumab as standard of care + sEphB4-HSA in chemotherapy ineligible or chemotherapy refusing patients with metastatic urothelial carcinoma.

For More Information: Sarcoma Oncology Center. Santa Monica, California. Tel: (310) 552-9999

------------------------------------------------------------------------------------------------------------------------------------

For Pre-Approval access to sEphB4-HSA, please see our Investigational Drug Expanded Access Policy.

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

To the extent statements contained in the following presentation are not descriptions of historical facts regarding the company, they should be considered “forward-looking statements,” as described in the private securities litigation reform act of 1995, that reflect management’s current beliefs and expectations. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “hope,” “hypothesis,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “will,” “would,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in these presentations include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) our ability to develop and manufacture our product candidates and to improve the manufacturing process; (v) our ability to attract and retain key scientific or management personnel; (vi) the anticipated timing of clinical data availability; (vii) our ability to meet our milestones; (viii) our expectations regarding our ability to obtain and maintain intellectual property protection; and (ix) the impact of capital market conditions on us. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to publicly update any forward-looking statements. The company’s investigational drug products have not been approved or cleared by the FDA.

Edit to add your HTML.